The EU Accession Process, Chinese Finance and Rising Corruption in Western Balkan Stabilitocracies: Serbia and Montenegro
Europe-Asia Studies · 14.09.2023 · 75 (8) · 1311-1335
DOI: 10.1080/09668136.2022.2115013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europe-Asia Studies, online erschienen am 21.09.2022. Verfasst von Digdem Soyaltin-Colella. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
As front runners in the EU accession process, Serbia and Montenegro have failed to control corruption yet managed to advance along the path to EU integration. Although they have stronger state capacity compared to other Western Balkan countries, the two have recently reverted to previous poor governance practices after initial headway meeting EU good governance conditions. An in-depth analysis of the two countries explains this paradox as the result of the combination of the EU accession process and increasing Chinese finance. While the EU’s stability-oriented strategy helped to consolidate these authoritarian regimes, Chinese funding policies have further strengthened patronage networks, fuelling corruption in the EU’s ‘stabilitocracies’.
Zitieren
APA
Soyaltin-Colella, D. (2023). The EU Accession Process, Chinese Finance and Rising Corruption in Western Balkan Stabilitocracies: Serbia and Montenegro. Europe-Asia Studies, 75(8), 1311-1335. https://doi.org/10.1080/09668136.2022.2115013
Vancouver
Soyaltin-Colella D. The EU Accession Process, Chinese Finance and Rising Corruption in Western Balkan Stabilitocracies: Serbia and Montenegro. Europe-Asia Studies. 2023;75(8):1311-1335. doi:10.1080/09668136.2022.2115013
BibTeX
@article{SoyaltinColella2023,
author = {Soyaltin-Colella, Digdem},
title = {The EU Accession Process, Chinese Finance and Rising Corruption in Western Balkan Stabilitocracies: Serbia and Montenegro},
journal = {Europe-Asia Studies},
year = {2023},
volume = {75},
number = {8},
pages = {1311--1335},
doi = {10.1080/09668136.2022.2115013}
}
EUVIMED